A new hope for men with metastatic prostate cancer

MUHC patients are the first enrolled in a new global Phase 1 clinical trial testing Actinium-225, a therapeutic agent used in nuclear precision medicine The Research Institute of McGill University Health Centre (RI‑MUHC) has enrolled this week the first patients to take part in an early-stage, multi-centre clinical trial of…